CA1151541A - Method for stimulating phagocytic activity and synergistic compositions therefor - Google Patents

Method for stimulating phagocytic activity and synergistic compositions therefor

Info

Publication number
CA1151541A
CA1151541A CA000361813A CA361813A CA1151541A CA 1151541 A CA1151541 A CA 1151541A CA 000361813 A CA000361813 A CA 000361813A CA 361813 A CA361813 A CA 361813A CA 1151541 A CA1151541 A CA 1151541A
Authority
CA
Canada
Prior art keywords
phagocytosis
muas
concentration
effect
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000361813A
Other languages
English (en)
French (fr)
Inventor
Endre A. Balazs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1151541A publication Critical patent/CA1151541A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA000361813A 1979-10-15 1980-10-08 Method for stimulating phagocytic activity and synergistic compositions therefor Expired CA1151541A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/084,615 US4272522A (en) 1979-10-15 1979-10-15 Method for stimulating phagocytic activity and synergistic compositions therefor
US84,615 1979-10-15

Publications (1)

Publication Number Publication Date
CA1151541A true CA1151541A (en) 1983-08-09

Family

ID=22186108

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000361813A Expired CA1151541A (en) 1979-10-15 1980-10-08 Method for stimulating phagocytic activity and synergistic compositions therefor

Country Status (5)

Country Link
US (1) US4272522A (enExample)
JP (1) JPS5663921A (enExample)
CA (1) CA1151541A (enExample)
FR (1) FR2466990A1 (enExample)
GB (1) GB2060380B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
IT1212892B (it) * 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
JPS5995221A (ja) * 1982-11-20 1984-06-01 Mochida Pharmaceut Co Ltd 食細胞機能調節作用を有する医薬組成物
US4500676A (en) * 1983-12-15 1985-02-19 Biomatrix, Inc. Hyaluronate modified polymeric articles
US4487865A (en) * 1983-12-15 1984-12-11 Biomatrix, Inc. Polymeric articles modified with hyaluronate
JPS6147418A (ja) * 1984-08-13 1986-03-07 Seikagaku Kogyo Co Ltd ヒアルロン酸含有胃粘膜保護剤
US4801475A (en) * 1984-08-23 1989-01-31 Gregory Halpern Method of hydrophilic coating of plastics
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5099013A (en) * 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US4663233A (en) * 1985-10-24 1987-05-05 Universal High Technologies Lens with hydrophilic coating
DE3684887D1 (de) * 1985-11-29 1992-05-21 Biomatrix Inc Arzneistoffabgabesysteme auf basis von hyaluronan, dessen derivaten und salzen sowie verfahren zu deren herstellung.
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5102783A (en) * 1990-01-12 1992-04-07 Vetrepharm, Inc. Composition and method for culturing and freezing cells and tissues
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
JP4818608B2 (ja) * 2002-07-03 2011-11-16 ペリコール・サイエンス・インコーポレーテッド ヒアルロン酸の組成物および使用方法
AU2007295894B2 (en) * 2006-09-13 2013-10-17 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof

Also Published As

Publication number Publication date
FR2466990A1 (fr) 1981-04-17
JPS636048B2 (enExample) 1988-02-08
FR2466990B1 (enExample) 1984-07-27
US4272522A (en) 1981-06-09
GB2060380A (en) 1981-05-07
GB2060380B (en) 1983-08-10
JPS5663921A (en) 1981-05-30

Similar Documents

Publication Publication Date Title
CA1151541A (en) Method for stimulating phagocytic activity and synergistic compositions therefor
Laurent et al. Hyaluronan 1
Wright Crystal structure of a wheat germ agglutinin/glycophorin-sialoglycopeptide receptor complex. Structural basis for cooperative lectin-cell binding.
Laurent et al. The properties and turnover of hyaluronan
DORFMAN Polysaccharides of connective tissue
US4665060A (en) Therapeutic treatment employing oligosaccharides
Costello et al. Inhibition of neutrophil activation by alpha1-acid glycoprotein
Hovingh et al. Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates
AU634730B2 (en) Antithrombotic composition
Schulman et al. Localization of membrane-derived oligosaccharides in the outer envelope of Escherichia coli and their occurrence in other Gram-negative bacteria
JPH11507043A (ja) オリゴ糖化合物による細菌の阻害
Constantopoulos et al. The requirement for membrane sialic acid in the stimulation of phagocytosis by the natural tetrapeptide, tuftsin
Weir et al. Non-specific recognition mechanisms by mononuclear phagocytes
WO1993005167A1 (en) Cell-type specific heparan sulfate proteoglycans and their uses
Bennett et al. Structure and function of cholera toxin and hormone receptors
Berton et al. Superoxide release by peritoneal and bone marrow-derived mouse macrophages. Modulation by adherence and cell activation
US5532216A (en) Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
Kozel et al. Influence of opsonization conditions on C3 deposition and phagocyte binding of large-and small-capsule Cryptococcus neoformans cells
Kościelak et al. Activity of B-gene-specified galactosyltransferase in individuals with Bm phenotypes
Ginsburg et al. Bacteria and zymosan opsonized with histone, dextran sulfate, and polyanetholesulfonate trigger intense chemiluminescence in human blood leukocytes and platelets and in mouse macrophages: modulation by metabolic inhibitors in relation to leukocyte-bacteria interactions in inflammatory sites
Ponzin et al. Characterization of macrophages elicited by intraperitoneal injection of hyaluronate
Perry et al. Liver cell and macrophage surface lectins as determinants of recognition in blood clearance and cellular attachment of bacteria
JP2772878B2 (ja) マクロファージ活性化組成物
JP2007126453A (ja) ヒアルロナン産生促進剤及びヒアルロナン分解抑制剤
Cammarata et al. Mechanism of the antipeptic action of amylopectin sulfate (SN-263), an antiulcer, mucin-like agent

Legal Events

Date Code Title Description
MKEX Expiry